```html

Urogenital Schistosomiasis – Comprehensive Medical Guide

Overview

Urogenital schistosomiasis (also called urinary or genital schistosomiasis) is a chronic parasitic disease caused by the flatworm Schistosoma haematobium. The adult worms live in the veins surrounding the bladder and ureters, laying eggs that can become trapped in urinary and reproductive tissues.

It primarily affects people living in, or traveling to, endemic areas where freshwater is contaminated with the parasite. According to the World Health Organization (WHO), ≈112 million people worldwide are infected with S. haematobium, with the highest burden in sub‑Saharan Africa, the Middle East, and parts of the Arabian Peninsula.<sup>1</sup> Children aged 5–15 are especially vulnerable because they are most likely to play or bathe in infested water.

Symptoms

Symptoms may appear weeks after the initial infection and can be intermittent. They range from mild urinary irritation to severe genital disease. Not everyone experiences noticeable signs, which is why routine screening is recommended in endemic regions.

Acute (Katayama) Phase – 2 weeks to 3 months after exposure

• Fever and chills – low‑grade to high‑grade.
• Headache, malaise, and muscle aches – resemble a flu‑like illness.
• Cough – from larvae migrating through the lungs.
• Eosinophilia – elevated eosinophil count on blood test.

Chronic Phase – months to years after infection

• Hematuria (blood in urine) – often painless and may be visible (macroscopic) or microscopic.
• Painful urination (dysuria) – burning sensation during micturition.
• Increased urinary frequency or urgency – especially at night (nocturia).
• Pelvic or lower abdominal pain – due to bladder wall inflammation.
• Urinary tract obstruction – caused by granulomas causing narrowing of ureters.
• Female genital lesions – vaginal itching, discharge, bleeding, or ulcerations.
• Male genital involvement – epididymitis, prostatitis, or penile lesions.
• Infertility – scarring of reproductive tracts in both sexes.
• Kidney damage – hydronephrosis or chronic kidney disease in severe obstruction.
• Bladder cancer – squamous cell carcinoma risk is increased after decades of infection.

Causes and Risk Factors

The disease is acquired when skin contacts freshwater containing S. haematobium cercariae (larval form). The parasites penetrate the skin, travel through the bloodstream to the lungs, then to the liver, and finally mature in the venous plexus surrounding the bladder.

Key risk factors

• Geographic exposure – living in or traveling to endemic rural areas where irrigation, dams, or lakes are used for domestic purposes.
• Water contact activities – swimming, wading, washing clothes, or fishing in contaminated water.
• Poverty and limited sanitation – lack of safe water supplies forces reliance on natural water bodies.
• Age – children play in water more frequently.
• Occupational exposure – farmers, fishermen, and sand harvesters.
• Immunocompromised state – HIV or malnutrition may exacerbate disease severity.

Diagnosis

Accurate diagnosis combines clinical suspicion with laboratory confirmation.

Laboratory tests

• Urine microscopy – detection of characteristic S. haematobium eggs in a filtered urine sample (ideally collected between 10 a.m. and 2 p.m when egg excretion peaks). Sensitivity improves with three consecutive samples.
• Serology – ELISA or immunoblot for antibodies; useful when egg detection is negative but exposure is suspected.
• Circulating antigen tests – CAA (circulating anodic antigen) assays provide quantitative parasite load; increasingly used in research and some clinical settings.
• Complete blood count – eosinophilia supports acute infection.

Imaging

• Ultrasound – assesses bladder wall thickening, ureteral dilation, hydronephrosis, and renal damage.
• CT or MRI – reserved for complicated cases, such as suspected bladder cancer or extensive pelvic fibrosis.

Endoscopic evaluation

In persistent hematuria or suspicion of neoplasia, cystoscopy may be performed to visualize bladder lesions and obtain biopsies.

Treatment Options

The cornerstone of therapy is a single dose of praziquantel, an anthelmintic that rapidly kills adult worms.

Medication

• Praziquantel – 40 mg/kg orally in a single dose (or 20 mg/kg twice in one day). WHO and CDC recommend re‑treatment after 6–12 weeks in heavy infections.
• Adjunctive corticosteroids – short courses may be used in severe acute inflammation (e.g., Katayama fever) to reduce tissue damage.

Procedures

• Endoscopic laser or resection – for obstructive bladder polyps or early cancer lesions.
• Ureteral stenting – temporary relief of obstruction while medical therapy clears the infection.

Lifestyle and supportive care

• Hydration – maintain adequate fluid intake to flush the urinary tract.
• Pain management – acetaminophen or NSAIDs for dysuria and cramps.
• Follow‑up urine microscopy at 3–6 months post‑treatment to confirm egg clearance.

Living with Urogenital Schistosomiasis

Even after successful treatment, many patients experience lingering urinary or reproductive symptoms. The following strategies help manage daily life:

• Regular medical review – annual urine exams for at‑risk individuals to detect reinfection early.
• Bladder training – timed voiding can reduce urgency and improve continence.
• Pelvic floor exercises – strengthen muscles that support bladder control.
• Sexual health counseling – discuss genital lesions with partners; treat concomitant infections (e.g., STIs) to prevent fertility complications.
• Nutrition – a balanced diet rich in iron and vitamins supports recovery, particularly after chronic blood loss.
• Mental health – chronic disease can cause anxiety; consider counseling or support groups.

Prevention

Because reinfection is common, community‑level interventions are essential.

• Safe water supply – provision of boreholes, treated piped water, or well‑maintained latrines reduces contact with contaminated sources.
• Snail control – mollusciciding (e.g., niclosamide) and environmental management (clearing vegetation, drainage) lower the intermediate host population.
• Health education – teach schools and communities about avoiding wading in stagnant water.
• Mass drug administration (MDA) – WHO recommends annual praziquantel (40 mg/kg) to school‑age children in endemic districts.
• Protective clothing – waterproof boots and trousers when unavoidable water contact occurs.
• Travel precautions – tourists should use safe water for bathing and avoid freshwater swimming in endemic regions.

Complications

If left untreated or recurrent, chronic urogenital schistosomiasis can lead to serious health problems:

• Upper urinary tract obstruction – hydronephrosis may progress to chronic kidney disease.
• Bladder fibrosis – causes reduced bladder capacity and irritative symptoms.
• Squamous cell carcinoma of the bladder – risk is 3–5 times higher than in uninfected populations.<sup>2</sup>
• Infertility – scarring of the uterus, fallopian tubes, or seminal vesicles.
• Pregnancy complications – increased risk of miscarriage, preterm labor, and low birth weight.
• Secondary bacterial infections – urinary stasis predisposes to pyelonephritis.

When to Seek Emergency Care

References

1. World Health Organization. Schistosomiasis Fact Sheet. 2023. https://www.who.int/news-room/fact-sheets/detail/schistosomiasis
2. Centers for Disease Control and Prevention. Urogenital Schistosomiasis – Clinical Features & Cancer Risk. 2022. https://www.cdc.gov/parasites/schistosomiasis/biology.html
3. Mayo Clinic. Schistosomiasis. 2024. https://www.mayoclinic.org/diseases-conditions/schistosomiasis
4. Cleveland Clinic. Parasitic Infections: Schistosomiasis. 2023. https://my.clevelandclinic.org/health/diseases/15711-schistosomiasis
5. NIH National Institute of Allergy and Infectious Diseases. Praziquantel Treatment Guidelines. 2022. https://www.niaid.nih.gov/diseases-conditions/schistosomiasis

```